- Global Pharma News & Resources

Binge Eating Disorder Pipeline Review, H2 2018 - Therapeutic Analysis of 7 Companies & Drug Profiles -

The "Binge Eating Disorder - Pipeline Review, H2 2018" drug pipelines has been added to's offering.

Binge Eating Disorder - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 6 respectively.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Binge Eating Disorder - Overview
  4. Binge Eating Disorder - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Binge Eating Disorder - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Binge Eating Disorder - Companies Involved in Therapeutics Development
  • Chronos Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Heptares Therapeutics Ltd
  • Novo Nordisk AS
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Sunovion Pharmaceuticals Inc

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 19-Oct-2018